Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 492-493

  Schroeder, V ^a   Kucher, N ^b   Kohler, H P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE DISEASE; ARTICLE; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; FIBRINOLYSIS; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; PHYSIOLOGY;

ACUTE DISEASE; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FIBRINOLYSIS; HUMANS; PULMONARY EMBOLISM; SEVERITY OF ILLNESS INDEX;

EID: 0142137407     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00112.x     Document Type: Article

References (9)

1. Bouma BN, Marx PF, Mosnier LO, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
2. Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-38.
3. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.
4. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
5. Kucher N, Luder CM, Dörnhöfer T, Windecker S, Meier B, Hess OM. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J 2002; in press.
6. Remy-Jardin M, Louvegny S, Remy J, Artaud D, Deschildre F, Bauchart JJ, Thery C, Duhamel A. Acute central thromboembolic disease: posttherapeutic follow-up with spiral CT angiography. Radiology 1997; 203: 173-80.
7. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 30 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
8. Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, Lourenço D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA. Identification of polymorphisms in the 50-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
9. Trégouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109: 191-7.